The United States is now deep into its worst measles year since the early 1990s, with confirmed infections stacking up across nearly every state just as federal reviewers prepare to decide whether the country keeps the elimination status it has held for a quarter century.
A surge that already broke last year's record
As of August 13, 2026, the CDC had confirmed 2,566 measles cases in 47 jurisdictions this year — a tally that includes every reporting state along with the District of Columbia and New York City, which the agency tracks apart from the rest of New York. That figure has already climbed past the entire 2025 total of 2,289 cases, itself the highest annual count the country had logged since 1991.
Of this year's cases, 94 percent — 2,407 of 2,566 — trace back to one of 38 identified outbreaks, compared with 48 separate outbreaks across all of 2025. Andrew Racine, who leads the American Academy of Pediatrics, described the toll as an "avoidable crisis that disproportionally hurts children," pointing to hospitalized infants and students pulled out of class for weeks at a time.
Who's catching it — and how badly
Children under five account for roughly one in five cases this year, while kids and teens between five and nineteen make up close to half of all patients — with the remaining share, close to a third, landing among adults twenty and older. Put together, about two-thirds of everyone infected this year is nineteen or younger, but that combined figure shouldn't be mistaken for the 5-to-19 group alone.
Hospitalizations have touched roughly 7 percent of this year's patients, an improvement from the 11 percent rate recorded in 2025. No deaths have been confirmed among 2026 cases so far, though three people — including two children — died from measles complications last year.
Vaccination status remains the clearest divide in the data: 93 percent of this year's patients were unvaccinated or had no documented immunization history. That gap traces back to a steady slide in childhood coverage — national MMR vaccination among kindergartners fell to 92.4 percent in the 2025–26 school year, down from 95.2 percent just six years earlier, leaving an estimated 280,000 kindergartners without documented protection. Herd immunity against measles generally requires coverage above 95 percent.
Why measles outruns almost every other virus
Few pathogens spread as efficiently as measles. In an unprotected group sharing close quarters with an infectious person, as many as nine out of ten will catch it, partly because the virus can linger in the air of a room after the infected person has already left. Patients are contagious for about four days before any rash appears and remain so for four days afterward — often before they realize they're sick.
First symptoms typically appear 11 to 12 days after exposure, beginning with fever, cough, a runny nose and watery, reddened eyes. Small white spots inside the cheeks — Koplik spots — often follow, and a blotchy rash usually breaks out two to four days later, starting at the hairline before working down the body over about a week. Complications can include ear infections, diarrhea, pneumonia, and, in rare cases, swelling of the brain that leaves lasting damage.
The shots built to stop it
There's no stand-alone measles vaccine sold in the U.S.; protection comes bundled into the combination MMR shot, or MMRV, which also covers chickenpox for children between one and twelve. Two doses block about 97 percent of infections, while a single dose still cuts risk by roughly 93 percent. Kids are routinely scheduled for their first shot at 12 to 15 months and their second between ages four and six; most adults only need to confirm they received both childhood doses.
A verdict looms in November — but not because of the ballot box
The nation's measles elimination status, granted in 2000, is now under formal review. A U.S. national verification committee met in mid-August to assess this year's outbreak data before forwarding its findings to the Pan American Health Organization, which is expected to announce its ruling in November.
That November date isn't new, and it isn't tied to the U.S. election calendar. PAHO originally planned to render its decision in mid-April 2026 but pushed the meeting back in early March, folding it instead into its regular annual verification meeting. The stated reason was to give U.S. and Mexican health authorities more time for genomic sequencing and a fuller analysis of the outbreaks that began in 2025 — not any connection to November's midterms.
